先前的研究调查了糖尿病药物与甲状腺癌之间的关联，但结果尚未得出结论。本研究采用孟德尔随机化方法来调查糖尿病药物与甲状腺癌（TC）之间的因果关系。暴露是六种主要的糖尿病药物目标，而结局是TC及其分化形式，包括乳头状甲状腺癌（PTC）和滤泡性甲状腺癌（联邦贸易委员会）。使用 IVW、MR-Egger 和加权中值方法进行孟德尔随机化。还进行了异质性、水平多效性和留一法测试。在欧洲人群中，SGLT2抑制剂与TC（OR 0.051，95% CI 0.006-0.465，P = 0.0082）以及PTC（OR 0.034，95% CI 0.003-0.411，P = 0.0079），而与 FTC 没有相关性。即使在应用 Bonferroni 校正后，这些发现仍然一致。证据表明，SGLT2 抑制剂可能是欧洲人群中 TC（尤其是 PTC）的潜在治疗靶点。然而，还需要进一步的大规模随机对照试验来验证它们降低和治疗这些类型癌症的风险的能力。© 2024。Springer-Verlag Italia S.r.l.，Springer Nature 的一部分。

Previous studies have investigated the association between diabetes medications and thyroid cancer, but the results have not been conclusive. This study used a Mendelian randomization approach to investigate the causal relationship between diabetes medications and thyroid cancer (TC).Exposures were six major diabetes medications target, while outcomes were TC and its differentiated forms, including papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). Mendelian randomization was conducted using IVW, MR-Egger, and weighted median methods. Tests for heterogeneity, horizontal pleiotropy, and leave-one-out were also performed.In European populations, SGLT2 inhibitors were significantly negatively associated with TC (OR 0.051, 95% CI 0.006-0.465, P = 0.0082) as well as PTC (OR 0.034, 95% CI 0.003-0.411, P = 0.0079), while no correlation was found with FTC. These findings remained consistent even after applying the Bonferroni correction.The evidence suggests that SGLT2 inhibitors could be potential therapeutic targets for TC, especially for PTC, in European populations. However, further large-scale randomized controlled trials are necessary to verify their ability to reduce the risk of and treat these types of cancer.© 2024. Springer-Verlag Italia S.r.l., part of Springer Nature.